There are 2789 resources available
1246P - A phase I dose-escalation study of mobocertinib (TAK-788), an oral tyrosine kinase inhibitor (TKI), in Japanese NSCLC patients
Presenter: Toyoaki Hida
Session: ePoster Display
1247P - Management of infusion-related reactions (IRRs) in patients receiving amivantamab
Presenter: Keunchil Park
Session: ePoster Display
1248P - Osimertinib and crizotinib cardiotoxicity: Are real-world studies the way forward?
Presenter: Hasan Kobat
Session: ePoster Display
1249P - Pharmacokinetic and dose finding study of osimertinib in patients with impaired renal function and low body weight
Presenter: Tetsunari Hase
Session: ePoster Display
1250P - Differences of immune microenvironment among NSCLC patients with various KRAS mutation types
Presenter: Kun Wang
Session: ePoster Display
1252P - Liquid biopsy to track KRAS G12C mutation at progressive disease in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: Gianluigi De Renzi
Session: ePoster Display
1254P - Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC
Presenter: Marina Chiara Garassino
Session: ePoster Display
1255P - Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
Presenter: Niels Reinmuth
Session: ePoster Display
1203P - The analysis of ALK fusion variants in 4991 EGFR/MET mutation-negative non-squamous non-small cell lung carcinomas (NSCLCs)
Presenter: Evgeny Imyanitov
Session: ePoster Display
1204P - Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain
Presenter: Ana Laura Ortega Granados
Session: ePoster Display